Recent advances on the role of tumor exosomes in immunosuppression and disease progression

Seminars in Cancer Biology

Volumn 22, Issue 4, 2012, Pages 342-349

  Filipazzi, Paola ^a   Bürdek, Maja ^a   Villa, Antonello ^b   Rivoltini, Licia ^a   Huber, Veronica ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Cancer treatment; Microvesicles; Myeloid derived suppressor cells; NK dysfunction; T cell apoptosis

Indexed keywords

AUTOCRINE EFFECT; BONE MARROW CELL; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER THERAPY; CELL EXPANSION; CELL FUNCTION; CELL INTERACTION; CELL VACUOLE; EFFECTOR CELL; EXOSOME; EXTRACELLULAR MATRIX; HUMAN; IMMUNOCOMPETENT CELL; NATURAL KILLER CELL; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; STROMA CELL; TUMOR CELL;

ANIMALS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; EXOSOMES; HUMANS; IMMUNE TOLERANCE; KILLER CELLS, NATURAL; MYELOID CELLS; NEOPLASMS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84862117665     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2012.02.005     Document Type: Review

References (109)

1. Harding C., Heuser J., Stahl P. Endocytosis and intracellular processing of transferrin and colloidal gold-transferrin in rat reticulocytes: demonstration of a pathway for receptor shedding. Eur J Cell Biol 1984, 35:256-263.
2. Pan B.T., Teng K., Wu C., Adam M., Johnstone R.M. Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. J Cell Biol 1985, 101:942-948.
3. Johnstone R.M., Adam M., Hammond J.R., Orr L., Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem 1987, 262:9412-9420.
4. Huotari J., Helenius A. Endosome maturation. EMBO J 2011, 30:3481-3500.
5. Simpson R.J., Lim J.W., Moritz R.L., Mathivanan S. Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics 2009, 6:267-283.
6. Fevrier B., Raposo G. Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr Opin Cell Biol 2004, 16:415-421.
7. Thery C., Ostrowski M., Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 2009, 9:581-593.
8. Bobrie A., Colombo M., Raposo G., Thery C. Exosome secretion: molecular mechanisms and roles in immune responses. Traffic 2011, 12:1659-1668.
9. Thery C., Amigorena S., Raposo G., Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol 2006, [chapter 3, unit 3.22].
10. Couzin J. Cell biology: the ins and outs of exosomes. Science 2005, 308:1862-1863.
11. Ciravolo V., Huber V., Ghedini G.C., Venturelli E., Bianchi F., Campiglio M., et al. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol 2012, 227:658-667.
12. Hedlund M., Nagaeva O., Kargl D., Baranov V., Mincheva-Nilsson L. Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells. PLoS One 2011, 6:e16899.
13. Parolini I., Federici C., Raggi C., Lugini L., Palleschi S., De Milito A., et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem 2009, 284:34211-34222.
14. Khan S., Jutzy J.M., Aspe J.R., McGregor D.W., Neidigh J.W., Wall N.R. Survivin is released from cancer cells via exosomes. Apoptosis 2011, 16:1-12.
15. Raposo G., Nijman H.W., Stoorvogel W., Liejendekker R., Harding C.V., Melief C.J., et al. B lymphocytes secrete antigen-presenting vesicles. J Exp Med 1996, 183:1161-1172.
16. Thery C., Boussac M., Veron P., Ricciardi-Castagnoli P., Raposo G., Garin J., et al. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol 2001, 166:7309-7318.
17. Andreola G., Rivoltini L., Castelli C., Huber V., Perego P., Deho P., et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 2002, 195:1303-1316.
18. Huber V., Fais S., Iero M., Lugini L., Canese P., Squarcina P., et al. Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology 2005, 128:1796-1804.
19. Kim J.W., Wieckowski E., Taylor D.D., Reichert T.E., Watkins S., Whiteside T.L. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res 2005, 11:1010-1020.
20. Wolfers J., Lozier A., Raposo G., Regnault A., Thery C., Masurier C., et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 2001, 7:297-303.
21. Dai S., Wei D., Wu Z., Zhou X., Wei X., Huang H., et al. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ther 2008, 16:782-790.
22. Navabi H., Croston D., Hobot J., Clayton A., Zitvogel L., Jasani B., et al. Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial. Blood Cells Mol Dis 2005, 35:149-152.
23. Clemente C.G., Mihm M.C., Bufalino R., Zurrida S., Collini P., Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996, 77:1303-1310.
24. Sato E., Olson S.H., Ahn J., Bundy B., Nishikawa H., Qian F., et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005, 102:18538-18543.
25. Pages F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005, 353:2654-2666.
26. van Oijen M., Bins A., Elias S., Sein J., Weder P., de Gast G., et al. On the role of melanoma-specific CD8+ T-cell immunity in disease progression of advanced-stage melanoma patients. Clin Cancer Res 2004, 10:4754-4760.
27. Gajewski T.F., Meng Y., Blank C., Brown I., Kacha A., Kline J., et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 2006, 213:131-145.
28. van Niel G., Porto-Carreiro I., Simoes S., Raposo G. Exosomes: a common pathway for a specialized function. J Biochem 2006, 140:13-21.
29. Iero M., Valenti R., Huber V., Filipazzi P., Parmiani G., Fais S., et al. Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ 2008, 15:80-88.
30. Rupp A.K., Rupp C., Keller S., Brase J.C., Ehehalt R., Fogel M., et al. Loss of EpCAM expression in breast cancer derived serum exosomes: role of proteolytic cleavage. Gynecol Oncol 2011, 122:437-446.
31. Andre F., Schartz N.E., Movassagh M., Flament C., Pautier P., Morice P., et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet 2002, 360:295-305.
32. Logozzi M., De Milito A., Lugini L., Borghi M., Calabro L., Spada M., et al. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One 2009, 4:e5219.
33. Taylor D.D., Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008, 110:13-21.
34. Mitchell P.J., Welton J., Staffurth J., Court J., Mason M.D., Tabi Z., et al. Can urinary exosomes act as treatment response markers in prostate cancer?. J Transl Med 2009, 7:4.
35. Al-Nedawi K., Meehan B., Rak J. Microvesicles: messengers and mediators of tumor progression. Cell Cycle 2009, 8:2014-2018.
36. Zitvogel L., Regnault A., Lozier A., Wolfers J., Flament C., Tenza D., et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998, 4:594-600.
37. Zhang Y., Luo C.L., He B.C., Zhang J.M., Cheng G., Wu X.H. Exosomes derived from IL-12-anchored renal cancer cells increase induction of specific antitumor response in vitro: a novel vaccine for renal cell carcinoma. Int J Oncol 2010, 36:133-140.
38. Van Parijs L., Abbas A.K. Role of Fas-mediated cell death in the regulation of immune responses. Curr Opin Immunol 1996, 8:355-361.
39. Osborne B.A. Apoptosis and the maintenance of homoeostasis in the immune system. Curr Opin Immunol 1996, 8:245-254.
40. Alderson M.R., Tough T.W., Davis-Smith T., Braddy S., Falk B., Schooley K.A., et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995, 181:71-77.
41. Suda T., Okazaki T., Naito Y., Yokota T., Arai N., Ozaki S., et al. Expression of the Fas ligand in cells of T cell lineage. J Immunol 1995, 154:3806-3813.
42. O'Connell J., Bennett M.W., O'Sullivan G.C., Collins J.K., Shanahan F. The Fas counterattack: cancer as a site of immune privilege. Immunol Today 1999, 20:46-52.
43. Hahne M., Rimoldi D., Schroter M., Romero P., Schreier M., French L.E., et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996, 274:1363-1366.
44. Abusamra A.J., Zhong Z., Zheng X., Li M., Ichim T.E., Chin J.L., et al. Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis. Blood Cells Mol Dis 2005, 35:169-173.
45. Bergmann C., Strauss L., Wieckowski E., Czystowska M., Albers A., Wang Y., et al. Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression. Head Neck 2009, 31:371-380.
46. Martinez-Lorenzo M.J., Anel A., Alava M.A., Pineiro A., Naval J., Lasierra P., et al. The human melanoma cell line MelJuSo secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles. Possible contribution to tumor counterattack. Exp Cell Res 2004, 295:315-329.
47. Qu J.L., Qu X.J., Qu J.L., Qu X.J., Zhao M.F., Teng Y.E., et al. The role of cbl family of ubiquitin ligases in gastric cancer exosome-induced apoptosis of Jurkat T cells. Acta Oncol 2009, 48:1173-1180.
48. Wieckowski E.U., Visus C., Szajnik M., Szczepanski M.J., Storkus W.J., Whiteside T.L. Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J Immunol 2009, 183:3720-3730.
49. Peng P., Yan Y., Keng S. Exosomes in the ascites of ovarian cancer patients: origin and effects on anti-tumor immunity. Oncol Rep 2011, 25:749-762.
50. Taylor D.D., Gercel-Taylor C. Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer 2005, 92:305-311.
51. Taylor D.D., Gercel-Taylor C., Lyons K.S., Stanson J., Whiteside T.L. T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res 2003, 9:5113-5119.
52. Klibi J., Niki T., Riedel A., Pioche-Durieu C., Souquere S., Rubinstein E., et al. Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood 2009, 113:1957-1966.
53. Clayton A., Al-Taei S., Webber J., Mason M.D., Tabi Z. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J Immunol 2011, 187:676-683.
54. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9:162-174.
55. Valenti R., Huber V., Filipazzi P., Pilla L., Sovena G., Villa A., et al. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res 2006, 66:9290-9298.
56. Filipazzi P., Valenti R., Huber V., Pilla L., Canese P., Iero M., et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007, 25:2546-2553.
57. Filipazzi P., Huber V., Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother 2012, 61:255-263.
58. Hoechst B., Ormandy L.A., Ballmaier M., Lehner F., Kruger C., Manns M.P., et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008, 135:234-243.
59. Yuan X.K., Zhao X.K., Xia Y.C., Zhu X., Xiao P. Increased circulating immunosuppressive CD14(+)HLA-DR(-/low) cells correlate with clinical cancer stage and pathological grade in patients with bladder carcinoma. J Int Med Res 2011, 39:1381-1391.
60. Brimnes M.K., Vangsted A.J., Knudsen L.M., Gimsing P., Gang A.O., Johnsen H.E., et al. Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol 2010, 72:540-547.
61. Szajnik M., Czystowska M., Szczepanski M.J., Mandapathil M., Whiteside T.L. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One 2010, 5:e11469.
62. Wada J., Onishi H., Suzuki H., Yamasaki A., Nagai S., Morisaki T., et al. Surface-bound TGF-beta1 on effusion-derived exosomes participates in maintenance of number and suppressive function of regulatory T-cells in malignant effusions. Anticancer Res 2010, 30:3747-3757.
63. Clayton A., Mitchell J.P., Court J., Mason M.D., Tabi Z. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res 2007, 67:7458-7466.
64. Wang G.J., Liu Y., Qin A., Shah S.V., Deng Z.B., Xiang X., et al. Thymus exosomes-like particles induce regulatory T cells. J Immunol 2008, 181:5242-5248.
65. Yu S., Liu C., Su K., Wang J., Liu Y., Zhang L., et al. Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol 2007, 178:6867-6875.
66. Xiang X., Poliakov A., Liu C., Liu Y., Deng Z.B., Wang J., et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer 2009, 124:2621-2633.
67. Liu Y., Xiang X., Zhuang X., Zhang S., Liu C., Cheng Z., et al. Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells. Am J Pathol 2010, 176:2490-2499.
68. Chalmin F., Ladoire S., Mignot G., Vincent J., Bruchard M., Remy-Martin J.P., et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest 2010, 120:457-471.
69. Xiang X., Liu Y., Zhuang X., Zhang S., Michalek S., Taylor D.D., et al. TLR2-mediated expansion of MDSCs is dependent on the source of tumor exosomes. Am J Pathol 2010, 177:1606-1610.
70. Mignot G., Chalmin F., Ladoire S., Rebe C., Ghiringhelli F. Tumor exosome-mediated MDSC activation. Am J Pathol 2011, 178:1403. 4; author reply 1404-5.
71. Clayton A., Tabi Z. Exosomes and the MICA-NKG2D system in cancer. Blood Cells Mol Dis 2005, 34:206-213.
72. Clayton A., Mitchell J.P., Court J., Linnane S., Mason M.D., Tabi Z. Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol 2008, 180:7249-7258.
73. Ashiru O., Boutet P., Fernandez-Messina L., Aguera-Gonzalez S., Skepper J.N., Vales-Gomez M., et al. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res 2010, 70:481-489.
74. Liu C., Yu S., Zinn K., Wang J., Zhang L., Jia Y., et al. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol 2006, 176:1375-1385.
75. Szczepanski M.J., Szajnik M., Welsh A., Whiteside T.L., Boyiadzis M. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. Haematologica 2011, 96:1302-1309.
76. Muralidharan-Chari V., Clancy J.W., Sedgwick A., D'Souza-Schorey C. Microvesicles: mediators of extracellular communication during cancer progression. J Cell Sci 2010, 123:1603-1611.
77. Hood J.L., Pan H., Lanza G.M., Wickline S.A. Consortium for translational research in advanced imaging and nanomedicine (C-TRAIN). Paracrine induction of endothelium by tumor exosomes. Lab Invest 2009, 89:1317-1328.
78. Hood J.L., San R.S., Wickline S.A. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res 2011, 71:3792-3801.
79. Chaput N., Thery C. Exosomes: immune properties and potential clinical implementations. Semin Immunopathol 2011, 33:419-440.
80. Richardson M.M., Jennings L.K., Zhang X.A. Tetraspanins and tumor progression. Clin Exp Metastasis 2011, 28:261-270.
81. Gesierich S., Berezovskiy I., Ryschich E., Zoller M. Systemic induction of the angiogenesis switch by the tetraspanin D6.1A/CO-029. Cancer Res 2006, 66:7083-7094.
82. Nazarenko I., Rana S., Baumann A., McAlear J., Hellwig A., Trendelenburg M., et al. Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res 2010, 70:1668-1678.
83. Sheldon H., Heikamp E., Turley H., Dragovic R., Thomas P., Oon C.E., et al. New mechanism for Notch signaling to endothelium at a distance by Delta-like 4 incorporation into exosomes. Blood 2010, 116:2385-2394.
84. Park J.E., Tan H.S., Datta A., Lai R.C., Zhang H., Meng W., et al. Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol Cell Proteomics 2010, 9:1085-1099.
85. Svensson K.J., Kucharzewska P., Christianson H.C., Skold S., Lofstedt T., Johansson M.C., et al. Hypoxia triggers a proangiogenic pathway involving cancer cell microvesicles and PAR-2-mediated heparin-binding EGF signaling in endothelial cells. Proc Natl Acad Sci USA 2011, 108:13147-13152.
86. Skog J., Wurdinger T., van Rijn S., Meijer D.H., Gainche L., Sena-Esteves M., et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008, 10:1470-1476.
87. Meckes D.G., Shair K.H., Marquitz A.R., Kung C.P., Edwards R.H., Raab-Traub N. Human tumor virus utilizes exosomes for intercellular communication. Proc Natl Acad Sci USA 2010, 107:20370-20375.
88. Yang M., Chen J., Su F., Yu B., Su F., Lin L., et al. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol Cancer 2011, 10:117.
89. Webber J., Steadman R., Mason M.D., Tabi Z., Clayton A. Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res 2010, 70:9621-9630.
90. Cho J.A., Park H., Lim E.H., Lee K.W. Exosomes from breast cancer cells can convert adipose tissue-derived mesenchymal stem cells into myofibroblast-like cells. Int J Oncol 2012, 40:130-138.
91. Nieuwland R., van der Post J.A., Lok C.A., Kenter G., Sturk A. Microparticles and exosomes in gynecologic neoplasias. Semin Thromb Hemost 2010, 36:925-929.
92. Jung T., Castellana D., Klingbeil P., Cuesta Hernandez I., Vitacolonna M., Orlicky D.J., et al. CD44v6 dependence of premetastatic niche preparation by exosomes. Neoplasia 2009, 11:1093-1105.
93. Raman D., Baugher P.J., Thu Y.M., Richmond A. Role of chemokines in tumor growth. Cancer Lett 2007, 256:137-165.
94. Lu T., Sathe S.S., Swiatkowski S.M., Hampole C.V., Stark G.R. Secretion of cytokines and growth factors as a general cause of constitutive NFkappaB activation in cancer. Oncogene 2004, 23:2138-2145.
95. Daughaday W.H., Deuel T.F. Tumor secretion of growth factors. Endocrinol Metab Clin North Am 1991, 20:539-563.
96. Goustin A.S., Leof E.B., Shipley G.D., Moses H.L. Growth factors and cancer. Cancer Res 1986, 46:1015-1029.
97. Al-Nedawi K., Meehan B., Micallef J., Lhotak V., May L., Guha A., et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 2008, 10:619-624.
98. Higginbotham J.N., Demory Beckler M., Gephart J.D., Franklin J.L., Bogatcheva G., Kremers G.J., et al. Amphiregulin exosomes increase cancer cell invasion. Curr Biol 2011, 21:779-786.
99. Ostrowski M., Carmo N.B., Krumeich S., Fanget I., Raposo G., Savina A., et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol 2010, 12:19. 30; sup pp 1-13.
100. Hendrix A., Westbroek W., Bracke M., De Wever O. An ex(o)citing machinery for invasive tumor growth. Cancer Res 2010, 70:9533-9537.
101. Luciani F., Spada M., De Milito A., Molinari A., Rivoltini L., Montinaro A., et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst 2004, 96:1702-1713.
102. Chen K.G., Valencia J.C., Lai B., Zhang G., Paterson J.K., Rouzaud F., et al. Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. Proc Natl Acad Sci USA 2006, 103:9903-9907.
103. Safaei R., Larson B.J., Cheng T.C., Gibson M.A., Otani S., Naerdemann W., et al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther 2005, 4:1595-1604.
104. Yin J., Yan X., Yao X., Zhang Y., Shan Y., Mao N., et al. Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients. J Cell Mol Med 2012, 16:337-348.
105. Lehmann B.D., McCubrey J.A., Jefferson H.S., Paine M.S., Chappell W.H., Terrian D.M. A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. Cell Cycle 2007, 6:595-605.
106. Yu X., Harris S.L., Levine A.J. The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res 2006, 66:4795-4801.
107. Lehmann B.D., Paine M.S., Brooks A.M., McCubrey J.A., Renegar R.H., Wang R., et al. Senescence-associated exosome release from human prostate cancer cells. Cancer Res 2008, 68:7864-7871.
108. Battke C., Ruiss R., Welsch U., Wimberger P., Lang S., Jochum S., et al. Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC. Cancer Immunol Immunother 2011, 60:639-648.
109. Aung T., Chapuy B., Vogel D., Wenzel D., Oppermann M., Lahmann M., et al. Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. Proc Natl Acad Sci USA 2011, 108:15336-15341.